You are here: Home: BCU 9 | 2005: Breast Cancer Journal Club Notes


Cancer 2005;104(2):236-9. Abstract


As second-line therapy, fulvestrant was as effective as anastrozole in terms of time to disease progression and objective response rates.


A prospectively planned, combined, overall survival analysis was performed on data from two Phase III trials that compared fulvestrant (250 mg monthly; n = 428) with anastrozole (1 mg daily; n = 423) in the treatment of postmenopausal women with advanced breast carcinoma who had disease progression after receipt of previous endocrine treatment.


  • Prolonged survival was observed with both drugs, with 10 to 20 percent of patients still alive >5 years after randomization.
  • Median overall survival was 27.4 months and 27.7 months in fulvestrant and anastrozole-treated patients, respectively (hazard ratio, 0.98; p = 0.809).


Bundred NJ et al. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res 2002;22(4):2317-9. Abstract

Carlson RW. The history and mechanism of action of fulvestrant. Clin Breast Cancer 2005;6(Suppl 1):5-8. Abstract

Dodwell D, Vergote I. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rev 2005;31(4):274-82. Abstract

Franco S et al. Response to fulvestrant in heavily pretreated postmenopausal women: A single-center experience. Breast Cancer Res Treat 2004;88(2):103-8. Abstract

Howell A. The future of fulvestrant (“Faslodex”). Cancer Treat Rev 2005;31(Suppl 2):26-33. Abstract

Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract

Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403. Abstract

Johnston SR et al. Life following aromatase inhibitors — Where now for endocrine sequencing? Breast Cancer Res Treat 2005;93(Suppl 1):19-25. Abstract

Jones SE, Pippen J. Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 2005;6(Suppl 1):9-14. Abstract

Mauriac L et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials. Eur J Cancer 2003;39(9):1228-33. Abstract

Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract

Robertson JF et al. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005;92(2):169-74. Abstract

Vergote I et al; Trial 0020 Investigators; Trial 0021 Investigators. Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79(2):207-11. Abstract



Editor’s Note:
Cheetos and raisins for dinner: The curse of Wilma and why a public sector that can’t figure out a way to get electricity to gas stations seems unlikely to
be victorious in the “war on cancer”
Harold J Burstein, MD, PhD
- Select publications
Charles L Vogel, MD
- Select publications
Eleftherios P Mamounas, MD, MPH
- Select publications
Journal Club

Breast Cancer Journal Club Notes

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Trastuzumab After Adjuvant Chemotherapy in HER2-Positive Breast Cancer

E2100: A Randomized Phase III Trial of Paclitaxel versus Paclitaxel Plus Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer (ABC) in Older Women

Fulvestrant versus Anastrozole for the Treatment of Advanced
Breast Carcinoma: A Prospectively Planned Combined Survival
Analysis of Two Multicenter Trials

Patterns of Care in Medical Oncology: A Case Survey Comparing Practices of Breast Cancer Investigators and General Oncologists — Section A: Adjuvant Endocrine Therapy


CME Information
Faculty Disclosures
Editor's Office